Neurotrauma Research

Laboratory Focus

We have completed a Phase I/IIA clinical trial to investigate the potential of a new therapy, BA-210 (Cethrin®), in acute spinal cord injury. BA-210 is a recombinant protein thought to promote neuroregeneration and neuroprotection in the central nervous system (CNS) (see reference 1). The first application of this medication in the world was at the Barrow Neurological Institute. As late as 2006, Barrow had the largest clinical experience with it in the world. Phase III human clinical trials are expected to begin soon.

Barrow researchers are also actively involved in numerous research protocols related to the imaging and cognitive functioning of patients with neurological injury.

Reference

Alseres Pharmaceuticals website, http://www.alseres.com/product-pipeline/product-candidates/cethrin.asp. Accessed December 2007. (This website link is provided for your convenience only. Barrow Neurological Institute neither endorses nor is responsible for the content on the site in any way.)